Pomerantz LLP Files Class Action Against LifeMD for Securities Fraud.
ByAinvest
Saturday, Sep 6, 2025 10:32 am ET1min read
LFMD--
The complaint, filed by Glancy Prongay & Murray LLP, alleges that LifeMD made materially false and misleading statements and failed to disclose material adverse facts about its business, operations, and prospects during the Class Period (May 7, 2025, to August 5, 2025) [1]. Specifically, the company is accused of overstating its competitive position and being reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment. These actions, the complaint argues, led to materially misleading statements about the company’s business, operations, and prospects.
On August 5, 2025, LifeMD announced that it was revising its full-year 2025 guidance due to temporary challenges facing its Rex MD business. This announcement resulted in a significant drop in the company’s stock price, falling $5.31 per share or 44.8% to close at $6.53 per share on August 6, 2025 [1].
Pomerantz LLP, a prominent law firm known for its work in corporate and securities litigation, is also investigating claims on behalf of LifeMD investors. Pomerantz LLP has advised investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, if they wish to join the class action [2].
Investors who believe they may have suffered losses due to these alleged practices are encouraged to contact Glancy Prongay & Murray LLP for more information. The firm can be reached at shareholders@glancylaw.com or by phone at 310-201-9150, toll-free at 888-773-9224. More details can be found on their website at www.glancylaw.com [1].
References:
[1] https://www.morningstar.com/news/business-wire/20250905627675/deadline-alert-lifemd-inc-lfmd-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-lifemd-inc-lfmd-ce7d59dbd88cf326
A class-action lawsuit has been filed against LifeMD, Inc. (NASDAQ: LFMD) alleging securities fraud or other unlawful business practices. The lawsuit concerns investors who purchased LifeMD securities during the class period. Those interested in joining the class action must ask the court to appoint them as Lead Plaintiff by October 27, 2025. The complaint can be obtained at pomerantzlaw.com.
Investors of LifeMD, Inc. (NASDAQ: LFMD) are urged to take note of a significant development. A class-action lawsuit has been filed against the company, alleging securities fraud and other unlawful business practices. The lawsuit targets investors who purchased LifeMD securities during the specified class period. Those interested in joining the class action must ask the court to appoint them as Lead Plaintiff by October 27, 2025 [1].The complaint, filed by Glancy Prongay & Murray LLP, alleges that LifeMD made materially false and misleading statements and failed to disclose material adverse facts about its business, operations, and prospects during the Class Period (May 7, 2025, to August 5, 2025) [1]. Specifically, the company is accused of overstating its competitive position and being reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment. These actions, the complaint argues, led to materially misleading statements about the company’s business, operations, and prospects.
On August 5, 2025, LifeMD announced that it was revising its full-year 2025 guidance due to temporary challenges facing its Rex MD business. This announcement resulted in a significant drop in the company’s stock price, falling $5.31 per share or 44.8% to close at $6.53 per share on August 6, 2025 [1].
Pomerantz LLP, a prominent law firm known for its work in corporate and securities litigation, is also investigating claims on behalf of LifeMD investors. Pomerantz LLP has advised investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, if they wish to join the class action [2].
Investors who believe they may have suffered losses due to these alleged practices are encouraged to contact Glancy Prongay & Murray LLP for more information. The firm can be reached at shareholders@glancylaw.com or by phone at 310-201-9150, toll-free at 888-773-9224. More details can be found on their website at www.glancylaw.com [1].
References:
[1] https://www.morningstar.com/news/business-wire/20250905627675/deadline-alert-lifemd-inc-lfmd-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-lifemd-inc-lfmd-ce7d59dbd88cf326
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet